<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Electrical storm and incessant ventricular tachycardia
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Electrical storm and incessant ventricular tachycardia
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Electrical storm and incessant ventricular tachycardia
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rod Passman, MD, MSCE
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mark S Link, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Todd F Dardas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 23, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Electrical storm, also referred to as arrhythmic storm, refers to multiple recurrences of ventricular arrhythmias over a short period of time. In most instances, the arrhythmia is ventricular tachycardia (VT), but polymorphic VT and ventricular fibrillation (VF) can also result in electrical storm. The arrhythmias can be self-terminating but frequently are terminated using antiarrhythmic drugs or device-related therapies (defibrillation or anti-tachycardia pacing).
        </p>
        <p>
         In contrast to repetitive ventricular arrhythmias occurring in electrical storm, incessant VT is defined as hemodynamically stable VT which persists for longer than one hour.
        </p>
        <p>
         This topic will discuss the incidence, triggers, clinical significance and treatment of electric storm and incessant VT. The general approach to the diagnosis and management of VT, as well as the use of implantable cardioverter-defibrillators, are discussed separately in various topics. (See
         <a class="medical medical_review" href="/z/d/html/1029.html" rel="external">
          "Sustained monomorphic ventricular tachycardia: Clinical manifestations, diagnosis, and evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1040.html" rel="external">
          "Sustained monomorphic ventricular tachycardia in patients with structural heart disease: Treatment and prognosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/91077.html" rel="external">
          "Primary prevention of sudden cardiac death in patients with cardiomyopathy and heart failure with reduced LVEF"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/946.html" rel="external">
          "Secondary prevention of sudden cardiac death in heart failure and cardiomyopathy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          DEFINITION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Electrical storm refers to a state of cardiac electrical instability characterized by multiple episodes of ventricular tachycardia (VT storm) or ventricular fibrillation (VF storm) within a relatively short period of time, typically 24 hours [
         <a href="#rid1">
          1
         </a>
         ]. The clinical definition of electrical storm is varied, somewhat arbitrary, and is a source of ongoing debate [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients
         <strong>
          without
         </strong>
         an implantable cardioverter-defibrillator (ICD), electrical storm has been variously defined as [
         <a href="#rid1">
          1,3-5
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The occurrence of three or more hemodynamically stable ventricular tachyarrhythmias within 24 hours
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         VT recurring soon after (within five minutes) termination of another VT episode
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Sustained and non-sustained VT resulting in a total number of ventricular ectopic beats greater than sinus beats in a 24-hour period
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients
         <strong>
          with
         </strong>
         an ICD, the most widely accepted definition of electrical storm is three or more appropriate therapies for ventricular tachyarrhythmias, including antitachycardia pacing or shocks, within 24 hours [
         <a href="#rid2">
          2,5-9
         </a>
         ]. However, this definition is not comprehensive as it fails to account for:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         VT that is slower than the programmed detection rate of the ICD
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         VT that fails to terminate with appropriate ICD therapy and remain undetected by the patient
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         VT that recurs soon after (within five minutes) a successful therapy are included by only some authors [
         <a href="#rid7">
          7,10
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         While electrical storm is defined by recurrent ventricular arrhythmia episodes or recurrent ICD therapies, incessant VT is defined as hemodynamically stable VT lasting longer than one hour.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          INCIDENCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The reported incidence of electrical storm varies widely based on the differences in the definition used, characteristics of the study population, device programming, and interpretation of intracardiac electrograms. The indication for implantable cardioverter-defibrillator (ICD) implantation (ie, primary versus secondary prevention) and type of underlying heart disease appear to be the most likely to influence the reported incidence of electrical storm. Most patients with electrical storm or incessant VT have severe underlying structural heart disease, although electrical storm or incessant VT has been less frequently reported in patients with structurally normal hearts (eg, Brugada syndrome or long QT syndrome). (See
         <a class="medical medical_review" href="/z/d/html/1036.html" rel="external">
          "Congenital long QT syndrome: Epidemiology and clinical manifestations"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/106759.html" rel="external">
          "Brugada syndrome: Clinical presentation, diagnosis, and evaluation"
         </a>
         .)
        </p>
        <p>
         When electrical storm is defined by &gt;2 VT/VF episodes requiring device intervention over a 24-hour period, the incidence is approximately 2 to 10 percent per year follow-up period in patients with ICDs [
         <a href="#rid2">
          2,6-8,11-17
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an analysis of 719 patients from the MADIT II study of primary prevention ICD implantation who were followed for an average of 21 months, 4 percent experienced electrical storm (2.3 percent per year) [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a single-center cohort of 955 patients who received an ICD (81 percent for primary prevention) and were followed for 4.5 years, 6.6 percent experienced electrical storm (1.5 percent per year) [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          TRIGGERS OF ELECTRICAL STORM
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with electrical storm or incessant VT have severe underlying structural heart disease, and studies have revealed an inciting factor in only a minority of patients with electrical storm. However, careful assessment is required as some of the known triggers are reversible, including [
         <a href="#rid9">
          9
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drug toxicity
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Electrolyte disturbances (ie, hypokalemia and hypomagnesemia)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         New or worsened heart failure
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute myocardial ischemia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thyrotoxicosis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         QT prolongation (which may be related to drug toxicity, electrolyte imbalance, or an underlying syndrome such as long QT syndrome)
        </p>
        <p>
        </p>
        <p>
         A circadian pattern of electrical storm seems likely as well, as shown in a meta-analysis of 246 patients from five cohorts, in which 29 percent of electrical storm episodes occurred between 8 AM and 10 AM (and 61 percent occurred between 8 AM and 4 PM) [
         <a href="#rid18">
          18
         </a>
         ]. These varied triggers highlight the complex interactions among anatomic substrate, autonomic tone, and cellular milieu that result in electrical storm.
        </p>
        <p class="headingAnchor" id="H5922518">
         <span class="h1">
          CLINICAL PRESENTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical presentation of electrical storm is highly variable but rarely if ever asymptomatic. One or more ventricular arrhythmias may be present, but monomorphic VT is the inciting arrhythmia in the vast majority of patients.
        </p>
        <p class="headingAnchor" id="H13768145">
         <span class="h2">
          Symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         The type and severity of symptoms from electrical storm depends on the ventricular rate, the presence of underlying heart disease, the degree of left ventricular systolic dysfunction, and the presence or absence of therapies delivered by an implantable cardioverter-defibrillator (ICD).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients
         <strong>
          without
         </strong>
         an ICD, the range of clinical presentations due to electrical storm spans from relatively minor symptoms such as repeated episodes of palpitations, presyncope, or syncope if the patient remains hemodynamically stable to cardiac arrest in those patients with hemodynamically unstable ventricular arrhythmias.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients
         <strong>
          with
         </strong>
         a preexisting ICD, electrical storm typically presents with multiple ICD therapies (some combination of anti-tachycardia pacing and ICD shocks depending on how the device is programmed to deliver therapy). However, patients with ventricular arrhythmias that are slower than the detection settings of the ICD may present in similar fashion as patients without an ICD.
        </p>
        <p>
        </p>
        <p>
         Patients with incessant VT may present with similar symptoms (eg, presyncope, syncope, palpitations, chest pain, dyspnea, etc), which again will vary depending on the ventricular rate and hemodynamic instability related to the VT. Rarely, when patients have incessant VT at slower rates (&lt;150 beats per minute), they may remain asymptomatic and hemodynamically stable for days or longer. In such cases, the initial presentation may be heart failure symptoms, suggesting that the incessant VT has resulted in tachycardia-mediated cardiomyopathy. (See
         <a class="medical medical_review" href="/z/d/html/1062.html" rel="external">
          "Arrhythmia-induced cardiomyopathy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13768179">
         <span class="h2">
          Electrocardiographic monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Electrical storm is not likely to be captured on a standard 12-lead electrocardiogram (ECG), given the brief 10-second window of time recorded with an ECG. Alternatively, continuous monitoring with either surface ECG (continuous ambulatory telemetry monitoring) or intracardiac electrograms (as recorded by an ICD) is required to document the presence, frequency, and duration of VT. A 12-lead ECG during incessant VT should be obtained whenever possible to help identify the mechanism and anatomic site of VT origin in order to help guide treatment.
        </p>
        <p>
         The electrocardiographic characteristics that are consistent with VT include a wide QRS complex occurring regularly at a rate of more than 100 beats per minute in association with one or more other distinct ECG characteristics (ie, AV dissociation, fusion beats, capture beats, etc). The ECG characteristics of VT are discussed in greater detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/920.html" rel="external">
          "Wide QRS complex tachycardias: Approach to the diagnosis", section on 'Evaluation of the electrocardiogram'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13768151">
         <span class="h2">
          Type of ventricular arrhythmia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Analyses of stored intracardiac electrograms (in patients with preexisting ICDs) recorded at the time of delivered therapies have provided insight into the arrhythmias responsible for electrical storm. The frequency of various ventricular arrhythmias is as follows [
         <a href="#rid6">
          6-8,10-13,15,16,19,20
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Monomorphic VT – 86 to 97 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Primary VF – 1 to 21 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mixed VT/VF – 3 to 14 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Polymorphic VT – 2 to 8 percent
        </p>
        <p>
        </p>
        <p>
         In patients with documented sustained arrhythmias prior to ICD implantation, there exists a significant correlation between the initial arrhythmia and that recorded during electrical storm. Patients with a prior history of VT are more likely to experience VT storm and a similar correlation is reported for patients with VF [
         <a href="#rid8">
          8,15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13768157">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of electrical storm is made when a patient has three or more confirmed episodes of ventricular tachyarrhythmia resulting in symptoms or implantable cardioverter-defibrillator (ICD) therapy within a 24-hour period. Typically, the episodes of arrhythmia are confirmed using continuous telemetry monitoring or by reviewing stored intracardiac electrograms from a patient's ICD. Given the likelihood of significant symptoms associated with electrical storm, the diagnosis is usually made in hospitalized patients (or in patients who have presented to the emergency department), though it is possible to make the diagnosis in outpatients whose cardiac activity is being continuously monitored (eg, patients with an ICD or wearing an ambulatory telemetry monitor).
        </p>
        <p>
         The diagnosis of incessant VT is made by confirming the presence of continuous VT for greater than one hour. As with electrical storm, given the likelihood of significant symptoms with incessant VT, the diagnosis is usually made in hospitalized patients (or in patients who have presented to the emergency department), though it is possible to make the diagnosis in outpatients whose cardiac activity is being continuously monitored (eg, patients with an ICD or wearing an ambulatory telemetry monitor). Rarely, when patients have incessant VT at slower rates (&lt;150 beats per minute), remaining asymptomatic and hemodynamically stable, the initial presentation may be related to tachycardia-mediated cardiomyopathy. (See
         <a class="medical medical_review" href="/z/d/html/1062.html" rel="external">
          "Arrhythmia-induced cardiomyopathy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13768172">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of electrical storm should be thought of differently depending on the presence or absence of an implantable cardioverter-defibrillator (ICD):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients
         <strong>
          without
         </strong>
         an ICD, the differential diagnosis includes the usual causes of a wide QRS complex tachycardia  (
         <a class="graphic graphic_table graphicRef51512" href="/z/d/graphic/51512.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with an ICD who receive multiple ICD shocks, the differential diagnosis includes the usual causes of a wide QRS complex tachycardia as well as the possibility of ICD malfunction (eg, electrical noise, oversensing, lead fracture, etc). (See
         <a class="medical medical_review" href="/z/d/html/989.html" rel="external">
          "Cardiac implantable electronic devices: Long-term complications", section on 'Inappropriate shocks'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Differentiating supraventricular tachycardia (SVT) with aberrant conduction from VT can usually be done by identifying P waves associated with every QRS complex (in contrast to the AV dissociation seen with VT) on a surface ECG or atrial activity associated with each ventricular activity on intracardiac electrogram. In patients who have received multiple ICD shock, device interrogation can quickly determine in the shocks were appropriate (in response to ventricular tachyarrhythmia) or inappropriate (ie, in response to an SVT or device malfunction).
        </p>
        <p>
         The differential diagnosis of incessant VT is similar to that of any wide QRS complex tachycardia  (
         <a class="graphic graphic_table graphicRef51512" href="/z/d/graphic/51512.html" rel="external">
          table 1
         </a>
         ). Most commonly, this would include atrial tachycardia or atrial flutter (with aberrant conduction), although any type of SVT must be considered.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with an acute and ongoing episode of electrical storm or incessant VT, initial treatment is based on hemodynamic stability or instability [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with hemodynamically unstable ventricular arrhythmias should initially undergo electrical cardioversion according to advanced cardiac life support protocol  (
         <a class="graphic graphic_algorithm graphicRef130747" href="/z/d/graphic/130747.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/278.html" rel="external">
          "Advanced cardiac life support (ACLS) in adults", section on 'Pulseless ventricular tachycardia and ventricular fibrillation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with electrical storm or incessant VT who are hemodynamically stable should be treated with both intravenous (IV) antiarrhythmic therapy and a beta blocker. We recommend IV
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         as the initial antiarrhythmic agent given its superior efficacy for terminating most ventricular arrhythmias. Additionally, because of the adrenergic surge associated with frequent ventricular tachyarrhythmias and defibrillator shocks, we recommend co-administration of a beta blocker, usually oral
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         . (See
         <a class="local">
          'Initial management'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with electrical storm or incessant VT in whom active myocardial ischemia is felt to be a contributing factor, urgent coronary revascularization should be pursued. (See
         <a class="medical medical_review" href="/z/d/html/68.html" rel="external">
          "Overview of the acute management of non-ST-elevation acute coronary syndromes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/66.html" rel="external">
          "Overview of the acute management of ST-elevation myocardial infarction"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5924401">
         <span class="h2">
          Initial management
         </span>
        </p>
        <p class="headingAnchor" id="H15429685">
         <span class="h3">
          ACLS and defibrillation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with electrical storm or incessant VT should be rapidly assessed for evidence of hemodynamic stability. Patients without a pulse or with other signs/symptoms of hemodynamic instability (ie, hypotension, active anginal-type chest pain or dyspnea, new changes in mental status, etc) should be promptly treated according to advanced cardiac life support (ACLS) protocol  (
         <a class="graphic graphic_algorithm graphicRef130747" href="/z/d/graphic/130747.html" rel="external">
          algorithm 1
         </a>
         ) with electrical cardioversion/defibrillation [
         <a href="#rid5">
          5,21
         </a>
         ]. ACLS is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/278.html" rel="external">
          "Advanced cardiac life support (ACLS) in adults", section on 'Pulseless ventricular tachycardia and ventricular fibrillation'
         </a>
         .)
        </p>
        <p>
         Patients who are successfully resuscitated from cardiac arrest associated with a ventricular arrhythmia are usually treated with antiarrhythmic therapy as well. (See
         <a class="local">
          'Initial antiarrhythmic medical therapy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H15429691">
         <span class="h3">
          Initial antiarrhythmic medical therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         While patients with electrical storm or incessant VT who are hemodynamically stable do not usually require emergent electrical cardioversion, urgent therapy is necessary to treat the ventricular arrhythmia(s) and reduce the effect of the adrenergic nervous system on the heart. Patients should be treated with both IV antiarrhythmic therapy and a beta blocker. Our approach to initial medical therapy is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We recommend IV
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         (150 mg IV over 10 minutes, followed by 1 mg/minute IV infusion for 6 hours, followed by 0.5 mg/minute IV infusion for 18 additional hours), rather than
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         , or no antiarrhythmic drug, as the initial antiarrhythmic agent given its superior efficacy for terminating most ventricular arrhythmias.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We recommend oral
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         (40 mg every 6 hours for the first 48 hours, with additional IV doses as needed for recurrent breakthrough ventricular arrhythmias) rather than a beta-1 selective beta blocker. Once the patient has stabilized, the patient should be transitioned to an oral beta blocker for long-term management. (See
         <a class="local">
          'Maintenance antiarrhythmic therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         This approach is in agreement with the 2017 AHA/ACC/HRS guidelines for the management of ventricular arrhythmias and the prevention of sudden cardiac death as well as the 2014 position paper from the European Heart Rhythm Association, both of which included recommendations for the management of electrical storm and incessant VT [
         <a href="#rid5">
          5,22
         </a>
         ]. Following stabilization, options for long-term arrhythmia control include catheter ablation or chronic oral antiarrhythmic therapy. (See
         <a class="local">
          'Subsequent management'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1421451357">
         <span class="h4">
          Amiodarone
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         has been shown in numerous trials to significantly improve survival from cardiac arrest and reduce the frequency of ventricular tachyarrhythmias [
         <a href="#rid23">
          23-26
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among a group of 504 patients with out-of-hospital cardiac arrest due to VF/VT who were not resuscitated following three or more external shocks and who were randomized to either IV
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         (300 mg) or placebo, patients who received amiodarone were significantly more like to survive to hospital admission (odds ratio 1.6, 95% CI 1.1-2.4) [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a randomized, double-blind dose ranging trial of 342 patients with electrical storm who received one of three IV doses of
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         (125 mg, 500 mg, or 1000 mg over the first 24 hours, with supplemental 150 mg IV doses as needed for recurrent VF/VT), patients in the 1000 mg group had an 88 percent reduction in ventricular arrhythmias in the initial 24 hours of therapy (compared with the 24 hours preceding therapy with amiodarone) [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among a group of 273 patients with recurrent VF/VT refractory to therapy with
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         , and bretylium who received
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         , 40 percent survived for 24 hours without any recurrent hemodynamically significant ventricular arrhythmias [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2008704977">
         <span class="h4">
          Beta blockers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Beta blockers are utilized to reduce the adrenergic surge associated with frequent ventricular tachyarrhythmias and defibrillator shocks. There is extensive evidence of the efficacy of beta blockers in patients with various cardiac conditions (eg, heart failure with reduced left ventricular systolic function, acute myocardial ischemia and/or infarction, etc) in which beta blockers reduced the impact of the sympathetic nervous system on the heart. Patients with electrical storm or incessant VT, particularly those who have received multiple defibrillations, will have increased sympathetic nervous system output, which can further predispose to additional arrhythmias, and they should be treated with a beta blocker along with antiarrhythmic drugs, unless contraindicated [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         Nonselective beta blockers such as
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         or
         <a class="drug drug_general" data-topicid="9672" href="/z/d/drug information/9672.html" rel="external">
          nadolol
         </a>
         are preferred over selective ones [
         <a href="#rid27">
          27
         </a>
         ]. Propranolol, a nonselective beta blocker, appears to be more effective than
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         , which is beta-1 selective. In a single-center, double-blind study of 60 patients with electrical storm, all patients received IV
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         and were randomized to propranolol (40 mg every 6 hours) or metoprolol (50 mg every 6 hours) for the first 48 hours [
         <a href="#rid28">
          28
         </a>
         ]. The primary end point (time to termination of ventricular arrhythmias) occurred significantly earlier in patients receiving propranolol (3 versus 18 hours with metoprolol), with 27 of 30 patients receiving propranolol free of ventricular arrhythmias within 24 hours (compared with 16 of 30 receiving metoprolol). Additionally, compared with the patients receiving metoprolol, patients receiving propranolol had significant improvement in several secondary end points, including lower rates of ventricular arrhythmias (incidence rate ratio 0.38, 95% CI 0.21-0.68) and implantable cardioverter-defibrillator (ICD) shocks (incidence rate ratio 0.43, 95% CI 0.23-0.89) during the ICU stay and shorter hospitalizations.
        </p>
        <p>
         The efficacy of sympathetic blockade was compared with conventional antiarrhythmic drugs in an observational study of 49 patients with electrical storm occurring up to 50 days after an acute myocardial infarction [
         <a href="#rid29">
          29
         </a>
         ]. Patients treated with sympathetic blockade (beta blockers or stellate ganglionic blockade) had a lower overall mortality compared with patients treated with conventional antiarrhythmics both at one week (22 versus 82 percent) and at one year (33 versus 95 percent).
        </p>
        <p class="headingAnchor" id="H3503376426">
         <span class="h4">
          Patients with an ICD
         </span>
         <span class="headingEndMark">
          —
         </span>
         Careful implantable cardiac-defibrillator (ICD) interrogation and assessment of programming are necessary in the setting of electrical storm. This ensures that delivered therapies are appropriate and that the ICD itself is not contributing to the event. Rare cases of pacing "permitted" or "facilitated" ventricular tachycardia (VT) or ventricular fibrillation (VF) have been reported where the pacing mode or programmed rate allows for proarrhythmic pauses or short-long-short sequences. [
         <a href="#rid30">
          30
         </a>
         ]. Anti-tachycardia pacing can also be proarrhythmic in that it may accelerate VT to ventricular flutter or VF.
        </p>
        <p class="headingAnchor" id="H15429721">
         <span class="h3">
          Coronary revascularization
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with electrical storm or incessant VT in whom active myocardial ischemia is felt to be a contributing factor, urgent coronary revascularization should be pursued as revascularization, and restoration of adequate coronary perfusion may be enough to resolve the ventricular tachyarrhythmias [
         <a href="#rid22">
          22,31,32
         </a>
         ]. Urgent coronary revascularization is discussed in greater detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/68.html" rel="external">
          "Overview of the acute management of non-ST-elevation acute coronary syndromes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/66.html" rel="external">
          "Overview of the acute management of ST-elevation myocardial infarction"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5006831">
         <span class="h2">
          Subsequent management
         </span>
        </p>
        <p class="headingAnchor" id="H5924486">
         <span class="h3">
          Catheter ablation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Catheter ablation of ventricular tachyarrhythmias is an important and effective therapy for electrical storm or incessant VT [
         <a href="#rid5">
          5,22,33-35
         </a>
         ]. For patients with electrical storm or incessant VT that persists or recurs in spite of medical therapy with
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         and a beta blocker, we recommend catheter ablation. Ablation for these conditions is a complex procedure with significant risk and should be performed in experienced centers capable of treating the recognized complications. Catheter ablation may also be considered in patients whose ventricular tachyarrhythmias are controlled with medical therapy but who are intolerant of medical therapy due to side effects. (See
         <a class="medical medical_review" href="/z/d/html/1007.html" rel="external">
          "Overview of catheter ablation of cardiac arrhythmias"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1040.html" rel="external">
          "Sustained monomorphic ventricular tachycardia in patients with structural heart disease: Treatment and prognosis", section on 'Radiofrequency catheter ablation'
         </a>
         .)
        </p>
        <p>
         Elimination of recurrent VT using catheter ablation techniques has long been available. Most reports of catheter ablation in electrical storm or incessant VT have been case reports or small retrospective single-center cohort studies. In a meta-analysis of 471 patients with electrical storm compiled from 39 publications (case reports and cohort studies), there was a high initial success rate for ablation of all ventricular arrhythmias (72 percent) along with a low procedural mortality rate (0.6 percent) and a relatively low recurrence rate of 6 percent over 61 weeks mean follow-up [
         <a href="#rid36">
          36
         </a>
         ]. In this review, the recurrence rate was significantly higher after ablation for electrical storm due to monomorphic VT compared with VF or polymorphic VT with underlying cardiomyopathy (odds ratio 3.8, 95% CI 1.7-8.6).
        </p>
        <p>
         In a multicenter case series of 1940 patients undergoing VT ablation, which was published after the meta-analysis, 677 patients (35 percent) had electrical storm; patients with electrical storm had a greater number of inducible VTs, required longer procedure times, and had a higher hospital mortality compared with those without storm (6.2 versus 1.4 percent) [
         <a href="#rid37">
          37
         </a>
         ]. At one-year follow-up, the risk of VT recurrence as detected by ICD interrogation was higher in the electrical storm group (32 versus 23 percent). Catheter ablation has also been used with reasonable success in patients with cardiogenic shock and refractory VT that together necessitated mechanical circulatory support; in one single-center experience with 21 such patients, 17 patients were successfully weaned from mechanical circulatory support following ablation, with 15 patients surviving to discharge and 13 surviving for at least one year post-ablation [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         The impact of catheter ablation on mortality in patients with electrical storm or incessant VT is not as clearly defined. In one single-center retrospective study of 52 patients with a first episode of electrical storm between 1995 and 2011 who were initially treated with pharmacologic therapy alone (29 patients) or catheter ablation (23 patients), the risk of recurrent electrical storm was significantly lower following catheter ablation, but there was no significant difference in survival over a median follow-up of 28 months [
         <a href="#rid39">
          39
         </a>
         ]. Compared with patients undergoing VT ablation in the absence of electrical storm in a large case series of 1940 patients, those with electrical storm had a higher one-year mortality (20.1 versus 8.5 percent; hazard ratio 1.5, 95% CI 1.1-2.1) [
         <a href="#rid37">
          37
         </a>
         ]. The high mortality seen in these patients is most likely related to the severity of underlying cardiac pathology in patients who present with electrical storm or incessant VT.
        </p>
        <p>
         The potential role of prophylactic catheter ablation for primary prevention of electrical storm in high-risk individuals is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1040.html" rel="external">
          "Sustained monomorphic ventricular tachycardia in patients with structural heart disease: Treatment and prognosis", section on 'Radiofrequency catheter ablation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2778532">
         <span class="h3">
          Maintenance antiarrhythmic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antiarrhythmic therapy should be maintained in the following patients:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who have undergone catheter ablation of their ventricular tachyarrhythmia, until there is evidence of no recurrent arrhythmias following the procedure, at which point the treating clinician may consider stopping the antiarrhythmic medication.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who have not undergone catheter ablation in whom stopping antiarrhythmic therapy would put them at risk for recurrent arrhythmias.
        </p>
        <p>
        </p>
        <p>
         Maintenance antiarrhythmic therapy is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/946.html" rel="external">
          "Secondary prevention of sudden cardiac death in heart failure and cardiomyopathy", section on 'Antiarrhythmic drugs'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1040.html" rel="external">
          "Sustained monomorphic ventricular tachycardia in patients with structural heart disease: Treatment and prognosis", section on 'Antiarrhythmic drugs'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H952447804">
         <span class="h3">
          ICD implantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         ICD implantation is contraindicated in patients with acute uncontrolled ventricular arrhythmias. However, once the patient has been treated successfully with maintenance antiarrhythmic therapy and catheter ablation, many patients will meet criteria for ICD implantation. (See
         <a class="medical medical_review" href="/z/d/html/921.html" rel="external">
          "Implantable cardioverter-defibrillators: Overview of indications, components, and functions", section on 'Indications'
         </a>
         .)
        </p>
        <p>
         In the small minority of patients with electrical storm due to reversible triggers, eventual ICD implantation will not be necessary once the trigger is removed. These patients should also have no other indication for ICD implantation. (See
         <a class="local">
          'Triggers of electrical storm'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H5007407">
         <span class="h3">
          Condition-specific therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         While general measures are appropriate for most patients, targeted therapies are indicated for specific conditions.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Specific arrythmias
         </strong>
         – Pause-dependent torsades de pointes can be effectively treated with pacing, and incessant arrhythmias associated with Brugada syndrome may be suppressed with
         <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">
          quinidine
         </a>
         or
         <a class="drug drug_general" data-topicid="8578" href="/z/d/drug information/8578.html" rel="external">
          isoproterenol
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/1036.html" rel="external">
          "Congenital long QT syndrome: Epidemiology and clinical manifestations"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/106760.html" rel="external">
          "Brugada syndrome or pattern: Management and approach to screening of relatives"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiomyopathy
         </strong>
         – For the majority of patients in whom a cardiomyopathy will be present, appropriate heart failure therapies should be prescribed and titrated to maximally tolerated doses. (See
         <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">
          "Overview of the management of heart failure with reduced ejection fraction in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ischemia
         </strong>
         – For patients in whom myocardial ischemia was the precipitating factor and who underwent revascularization, appropriate antithrombotic and anti-ischemic therapies should be prescribed. (See
         <a class="medical medical_review" href="/z/d/html/68.html" rel="external">
          "Overview of the acute management of non-ST-elevation acute coronary syndromes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/66.html" rel="external">
          "Overview of the acute management of ST-elevation myocardial infarction"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxic and/or metabolic factors
         </strong>
         – Correction of any identified inciting factors should occur. This may include removal of any offending drugs (eg, prescription or illicit drugs that prolong the QT interval) and correction of any electrolyte disturbances (ie, hypokalemia, hypomagnesemia, etc).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5006959">
         <span class="h2">
          Management of refractory cases
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rarely, patients will continue to have refractory electrical storm or incessant VT in spite of medical therapy and catheter ablation attempts. A variety of salvage therapies may be considered, in conjunction with the standard therapies discussed above, when the other treatments have been unsuccessful, including [
         <a href="#rid40">
          40-45
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thoracic epidural anesthesia and/or general anesthesia [
         <a href="#rid41">
          41,43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Insertion of an intraaortic balloon pump or a temporary ventricular assist device. In appropriate patients, these devices may help stabilize patients with refractory recurrent VT until ablation or surgical treatment can be performed. (See
         <a class="medical medical_review" href="/z/d/html/1482.html" rel="external">
          "Intraaortic balloon pump counterpulsation", section on 'Refractory ventricular arrhythmias'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1492.html" rel="external">
          "Short-term mechanical circulatory assist devices"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stellate ganglion block (SGB; usually left-sided). In aggregate, case series of patients treated with SGB show a reduction in episodes of VT and ICD shocks [
         <a href="#rid45">
          45-50
         </a>
         ]. In the largest reported case series of 30 patients with drug-refractory electrical storm, among whom 15 underwent left and 15 underwent bilateral SGB, 18 patients (60 percent) were free of VT at 24 hours, with an overall reduction in VT burden of 92 percent over the initial 72 hours [
         <a href="#rid51">
          51
         </a>
         ]. A study of 11 patients who underwent an SGB for electrical storm followed patients for sustained cessation of electrical storm for 24 hours. Cessation of electrical storm for 24 hours was achieved in 90 percent of patients after left SGB. Similarly, 90 percent of patients had no documented episodes of ventricular arrhythmias requiring intervention within six hours after SGB [
         <a href="#rid50">
          50
         </a>
         ]. In a first-in-man case series, transcutaneous magnetic stimulation of the left stellate ganglion significantly reduced episodes of VT and shocks for 48 to 72 hours in five patients with VT storm [
         <a href="#rid52">
          52
         </a>
         ]. SGB is a temporizing measure, and terminal sympathectomy via surgical cardiac sympathetic denervation (CSD) or orthotopic heart transplantation may be needed for eligible non-responders in whom other treatments have also failed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CSD, with one series suggesting bilateral CSD, is more efficacious than isolated left CSD [
         <a href="#rid5">
          5,40-42,44,46,53-55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiac transplantation. (See
         <a class="medical medical_review" href="/z/d/html/3528.html" rel="external">
          "Heart transplantation in adults: Indications and contraindications", section on 'Indications for transplantation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Renal artery denervation (RDN), with one small series of four patients showing marked decrease in the frequency of VT episodes following RDN [
         <a href="#rid56">
          56,57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of five patients with refractory VT, stereotactic body radiation therapy reduced the number of VT episodes by 99.9 percent, although the benefit was not quite as significant in a second study of 10 patients (88 percent reduction in VT) [
         <a href="#rid58">
          58,59
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H250695">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Electrical storm is generally associated with poor outcomes, with most studies reporting an association between electrical storm and cardiovascular mortality [
         <a href="#rid7">
          7,10,15
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the AVID trial, electrical storm was a significant independent risk factor for cardiac, non-sudden death (relative risk 2.4), which occurred most frequently within three months [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The MADIT II trial found that patients with electrical storm had a 7.4-fold higher risk of death when compared with those without electrical storm, with a 17.8-fold increased risk of death within the first three months after storm onset [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         What is not clear is whether the ventricular tachyarrhythmias or repeated implantable cardioverter-defibrillator (ICD) shocks themselves contribute to cardiac mortality or are secondary to a degenerating cardiac status. A potential mechanism was suggested by the experimental observation that recurrent ventricular fibrillation (VF) results in increases in intracellular calcium concentrations which might contribute to deterioration of left ventricular systolic function [
         <a href="#rid60">
          60,61
         </a>
         ]. Additionally, repeated shocks can cause myocardial injury leading to acute inflammation and fibrosis [
         <a href="#rid62">
          62-64
         </a>
         ]. Lastly, myocardial injury or stunning from recurrent defibrillations may activate the neurohormonal cascade responsible for worsening heart failure and cardiovascular mortality [
         <a href="#rid29">
          29,65,66
         </a>
         ]. Additional studies are needed to clarify these issues.
        </p>
        <p>
         Electrical storm, particularly when associated with repeated ICD discharges, may induce long-term anxiety that impacts overall health-related quality of life [
         <a href="#rid6">
          6,10,11,13,67
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/989.html" rel="external">
          "Cardiac implantable electronic devices: Long-term complications", section on 'Quality of life'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1046571806">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112260.html" rel="external">
          "Society guideline links: Arrhythmias in adults"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/112356.html" rel="external">
          "Society guideline links: Cardiac implantable electronic devices"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/115586.html" rel="external">
          "Society guideline links: Ventricular arrhythmias"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/116932.html" rel="external">
          "Society guideline links: Catheter ablation of arrhythmias"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H199200961">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics links (see
         <a class="medical medical_basics" href="/z/d/html/17131.html" rel="external">
          "Patient education: Ventricular tachycardia (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5922177">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Electrical storm, also referred to as arrhythmic storm, refers to multiple recurrences of ventricular arrhythmias over a short period of time, while incessant ventricular tachycardia (VT) is defined as hemodynamically stable VT which persists for hours. In most instances, the arrhythmia is monomorphic VT, but polymorphic VT and ventricular fibrillation (VF) can also result in electrical storm. The definition of electrical storm is different in patients with and without an implantable cardioverter-defibrillator (ICD). (See
         <a class="local">
          'Definition'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Triggers of electrical storm
         </strong>
         – Common triggers of electrical storm or incessant VT include drug toxicity, electrolyte disturbances, new or worsened heart failure, and acute myocardial ischemia, although a single inciting factor is not identified in the majority of patients. (See
         <a class="local">
          'Triggers of electrical storm'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         –
         <strong>
         </strong>
         The clinical presentations of electrical storm and incessant are highly variable but rarely if ever asymptomatic. (See
         <a class="local">
          'Clinical presentation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In patients
         <strong>
          without
         </strong>
         an ICD, the range of clinical presentations due to electrical storm spans from relatively minor symptoms such as repeated episodes of palpitations, presyncope, or syncope if the patient remains hemodynamically stable to cardiac arrest in those patients with hemodynamically unstable ventricular arrhythmias.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In patients
         <strong>
          with
         </strong>
         a preexisting ICD, electrical storm typically presents with multiple ICD therapies (some combination of anti-tachycardia pacing and ICD shocks depending on how the device is programmed to deliver therapy). However, patients with ventricular arrhythmias that are slower than the detection settings of the ICD may present in similar fashion as patients without an ICD.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of electrical storm is made when a patient has three or more confirmed episodes of ventricular tachyarrhythmia resulting in symptoms or ICD therapy within a 24-hour period. Typically, the episodes of arrhythmia are confirmed using continuous telemetry monitoring or by reviewing stored intracardiac electrograms from a patient's ICD. The diagnosis of incessant VT is made by confirming the presence of continuous VT for greater than one hour. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – The initial treatment approach to patients with electrical storm or incessant VT is based on hemodynamic stability or instability.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with hemodynamically unstable ventricular arrhythmias should initially undergo electrical cardioversion according to advanced cardiac life support protocol  (
         <a class="graphic graphic_algorithm graphicRef130747" href="/z/d/graphic/130747.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/278.html" rel="external">
          "Advanced cardiac life support (ACLS) in adults", section on 'Pulseless ventricular tachycardia and ventricular fibrillation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with electrical storm or incessant VT who are hemodynamically stable should be treated with both intravenous (IV) antiarrhythmic therapy and a beta blocker.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         We recommend IV
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         , rather than
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         , or no antiarrhythmic drug, as the initial antiarrhythmic agent given its superior efficacy for terminating most ventricular arrhythmias (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Amiodarone should be given as 150 mg IV over 10 minutes, followed by 1 mg/minute IV infusion for 6 hours, followed by 0.5 mg/minute IV infusion for 18 additional hours.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         We recommend the nonselective beta blocker
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         rather than a beta-1 selective beta blocker because of its increased efficacy in terminating VT (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Propranolol should be given as 40 mg oral doses every 6 hours for the first 48 hours, with additional IV doses as needed for recurrent breakthrough ventricular arrhythmias. (See
         <a class="local">
          'Initial management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with electrical storm or incessant VT in whom active myocardial ischemia is felt to be a contributing factor, urgent coronary revascularization should be pursued. (See
         <a class="medical medical_review" href="/z/d/html/68.html" rel="external">
          "Overview of the acute management of non-ST-elevation acute coronary syndromes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/66.html" rel="external">
          "Overview of the acute management of ST-elevation myocardial infarction"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Subsequent management
         </strong>
         – The subsequent management of patients with electrical storm or incessant VT is focused on the prevention of recurrent ventricular tachyarrhythmias.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with electrical storm or incessant VT that persists or recurs in spite of medical therapy with
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         and a beta blocker, we recommend catheter ablation (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). (See
         <a class="local">
          'Catheter ablation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Most patients will require at least a short course of maintenance antiarrhythmic therapy. (See
         <a class="local">
          'Maintenance antiarrhythmic therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients should also receive medical therapy aimed at the likely underlying cardiac pathology (eg, beta blockers and ACE-inhibitors in patients with heart failure and cardiomyopathy, anti-thrombotic and anti-ischemic therapy for patients with myocardial ischemia). (See
         <a class="local">
          'Condition-specific therapies'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Kowey PR. An overview of antiarrhythmic drug management of electrical storm. Can J Cardiol 1996; 12 Suppl B:3B.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Israel CW, Barold SS. Electrical storm in patients with an implanted defibrillator: a matter of definition. Ann Noninvasive Electrocardiol 2007; 12:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kowey PR, Levine JH, Herre JM, et al. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group. Circulation 1995; 92:3255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hariman RJ, Hu DY, Gallastegui JL, et al. Long-term follow-up in patients with incessant ventricular tachycardia. Am J Cardiol 1990; 66:831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2018; 72:e91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Credner SC, Klingenheben T, Mauss O, et al. Electrical storm in patients with transvenous implantable cardioverter-defibrillators: incidence, management and prognostic implications. J Am Coll Cardiol 1998; 32:1909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Exner DV, Pinski SL, Wyse DG, et al. Electrical storm presages nonsudden death: the antiarrhythmics versus implantable defibrillators (AVID) trial. Circulation 2001; 103:2066.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sesselberg HW, Moss AJ, McNitt S, et al. Ventricular arrhythmia storms in postinfarction patients with implantable defibrillators for primary prevention indications: a MADIT-II substudy. Heart Rhythm 2007; 4:1395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haegeli LM, Della Bella P, Brunckhorst CB. Management of a Patient With Electrical Storm: Role of Epicardial Catheter Ablation. Circulation 2016; 133:672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gatzoulis KA, Andrikopoulos GK, Apostolopoulos T, et al. Electrical storm is an independent predictor of adverse long-term outcome in the era of implantable defibrillator therapy. Europace 2005; 7:184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bänsch D, Böcker D, Brunn J, et al. Clusters of ventricular tachycardias signify impaired survival in patients with idiopathic dilated cardiomyopathy and implantable cardioverter defibrillators. J Am Coll Cardiol 2000; 36:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stuber T, Eigenmann C, Delacrétaz E. Characteristics and relevance of clustering ventricular arrhythmias in defibrillator recipients. Pacing Clin Electrophysiol 2005; 28:702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hohnloser SH, Al-Khalidi HR, Pratt CM, et al. Electrical storm in patients with an implantable defibrillator: incidence, features, and preventive therapy: insights from a randomized trial. Eur Heart J 2006; 27:3027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arya A, Haghjoo M, Dehghani MR, et al. Prevalence and predictors of electrical storm in patients with implantable cardioverter-defibrillator. Am J Cardiol 2006; 97:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verma A, Kilicaslan F, Marrouche NF, et al. Prevalence, predictors, and mortality significance of the causative arrhythmia in patients with electrical storm. J Cardiovasc Electrophysiol 2004; 15:1265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brigadeau F, Kouakam C, Klug D, et al. Clinical predictors and prognostic significance of electrical storm in patients with implantable cardioverter defibrillators. Eur Heart J 2006; 27:700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Streitner F, Kuschyk J, Veltmann C, et al. Predictors of electrical storm recurrences in patients with implantable cardioverter-defibrillators. Europace 2011; 13:668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guerra F, Bonelli P, Flori M, et al. Temporal Trends and Temperature-Related Incidence of Electrical Storm: The TEMPEST Study (Temperature-Related Incidence of Electrical Storm). Circ Arrhythm Electrophysiol 2017; 10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greene M, Newman D, Geist M, et al. Is electrical storm in ICD patients the sign of a dying heart? Outcome of patients with clusters of ventricular tachyarrhythmias. Europace 2000; 2:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fries R, Heisel A, Huwer H, et al. Incidence and clinical significance of short-term recurrent ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillator. Int J Cardiol 1997; 59:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorenek B, Blomström Lundqvist C, Brugada Terradellas J, et al. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. Europace 2014; 16:1655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med 1999; 341:871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheinman MM, Levine JH, Cannom DS, et al. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group. Circulation 1995; 92:3264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levine JH, Massumi A, Scheinman MM, et al. Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. Intravenous Amiodarone Multicenter Trial Group. J Am Coll Cardiol 1996; 27:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eifling M, Razavi M, Massumi A. The evaluation and management of electrical storm. Tex Heart Inst J 2011; 38:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2022; 43:3997.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chatzidou S, Kontogiannis C, Tsilimigras DI, et al. Propranolol Versus Metoprolol for Treatment of Electrical Storm in Patients With Implantable Cardioverter-Defibrillator. J Am Coll Cardiol 2018; 71:1897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nademanee K, Taylor R, Bailey WE, et al. Treating electrical storm : sympathetic blockade versus advanced cardiac life support-guided therapy. Circulation 2000; 102:742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sweeney MO, Ruetz LL, Belk P, et al. Bradycardia pacing-induced short-long-short sequences at the onset of ventricular tachyarrhythmias: a possible mechanism of proarrhythmia? J Am Coll Cardiol 2007; 50:614.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Authors/Task Force members, Windecker S, Kolh P, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35:2541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019; 40:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carbucicchio C, Santamaria M, Trevisi N, et al. Catheter ablation for the treatment of electrical storm in patients with implantable cardioverter-defibrillators: short- and long-term outcomes in a prospective single-center study. Circulation 2008; 117:462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deneke T, Shin DI, Lawo T, et al. Catheter ablation of electrical storm in a collaborative hospital network. Am J Cardiol 2011; 108:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan VH, Yap J, Hsu LF, Liew R. Catheter ablation of ventricular fibrillation triggers and electrical storm. Europace 2012; 14:1687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nayyar S, Ganesan AN, Brooks AG, et al. Venturing into ventricular arrhythmia storm: a systematic review and meta-analysis. Eur Heart J 2013; 34:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vergara P, Tung R, Vaseghi M, et al. Successful ventricular tachycardia ablation in patients with electrical storm reduces recurrences and improves survival. Heart Rhythm 2018; 15:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ballout JA, Wazni OM, Tarakji KG, et al. Catheter Ablation in Patients With Cardiogenic Shock and Refractory Ventricular Tachycardia. Circ Arrhythm Electrophysiol 2020; 13:e007669.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Izquierdo M, Ruiz-Granell R, Ferrero A, et al. Ablation or conservative management of electrical storm due to monomorphic ventricular tachycardia: differences in outcome. Europace 2012; 14:1734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz PJ, Priori SG, Cerrone M, et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation 2004; 109:1826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bourke T, Vaseghi M, Michowitz Y, et al. Neuraxial modulation for refractory ventricular arrhythmias: value of thoracic epidural anesthesia and surgical left cardiac sympathetic denervation. Circulation 2010; 121:2255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ajijola OA, Lellouche N, Bourke T, et al. Bilateral cardiac sympathetic denervation for the management of electrical storm. J Am Coll Cardiol 2012; 59:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burjorjee JE, Milne B. Propofol for electrical storm; a case report of cardioversion and suppression of ventricular tachycardia by propofol. Can J Anaesth 2002; 49:973.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaseghi M, Gima J, Kanaan C, et al. Cardiac sympathetic denervation in patients with refractory ventricular arrhythmias or electrical storm: intermediate and long-term follow-up. Heart Rhythm 2014; 11:360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meng L, Tseng CH, Shivkumar K, Ajijola O. Efficacy of Stellate Ganglion Blockade in Managing Electrical Storm: A Systematic Review. JACC Clin Electrophysiol 2017; 3:942.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cardona-Guarache R, Padala SK, Velazco-Davila L, et al. Stellate ganglion blockade and bilateral cardiac sympathetic denervation in patients with life-threatening ventricular arrhythmias. J Cardiovasc Electrophysiol 2017; 28:903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fudim M, Boortz-Marx R, Ganesh A, et al. Stellate ganglion blockade for the treatment of refractory ventricular arrhythmias: A systematic review and meta-analysis. J Cardiovasc Electrophysiol 2017; 28:1460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanghai S, Abbott NJ, Dewland TA, et al. Stellate Ganglion Blockade With Continuous Infusion Versus Single Injection for Treatment of Ventricular Arrhythmia Storm. JACC Clin Electrophysiol 2021; 7:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reinertsen E, Sabayon M, Riso M, et al. Stellate ganglion blockade for treating refractory electrical storm: a historical cohort study. Can J Anaesth 2021; 68:1683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel RA, Condrey JM, George RM, et al. Stellate ganglion block catheters for refractory electrical storm: a retrospective cohort and care pathway. Reg Anesth Pain Med 2023; 48:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tian Y, Wittwer ED, Kapa S, et al. Effective Use of Percutaneous Stellate Ganglion Blockade in Patients With Electrical Storm. Circ Arrhythm Electrophysiol 2019; 12:e007118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Markman TM, Hamilton RH, Marchlinski FE, Nazarian S. Case Series of Transcutaneous Magnetic Stimulation for Ventricular Tachycardia Storm. JAMA 2020; 323:2200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaseghi M, Barwad P, Malavassi Corrales FJ, et al. Cardiac Sympathetic Denervation for Refractory Ventricular Arrhythmias. J Am Coll Cardiol 2017; 69:3070.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Assis FR, Sharma A, Shah R, et al. Long-Term Outcomes of Bilateral Cardiac Sympathetic Denervation for Refractory Ventricular Tachycardia. JACC Clin Electrophysiol 2021; 7:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cauti FM, Rossi P, Bianchi S, et al. Outcome of a Modified Sympathicotomy for Cardiac Neuromodulation of Untreatable Ventricular Tachycardia. JACC Clin Electrophysiol 2021; 7:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Remo BF, Preminger M, Bradfield J, et al. Safety and efficacy of renal denervation as a novel treatment of ventricular tachycardia storm in patients with cardiomyopathy. Heart Rhythm 2014; 11:541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garg J, Shah S, Shah K, et al. Renal sympathetic denervation for the treatment of recurrent ventricular arrhythmias-ELECTRAM investigators. Pacing Clin Electrophysiol 2021; 44:865.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cuculich PS, Schill MR, Kashani R, et al. Noninvasive Cardiac Radiation for Ablation of Ventricular Tachycardia. N Engl J Med 2017; 377:2325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neuwirth R, Cvek J, Knybel L, et al. Stereotactic radiosurgery for ablation of ventricular tachycardia. Europace 2019; 21:1088.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaugg CE, Wu ST, Barbosa V, et al. Ventricular fibrillation-induced intracellular Ca2+ overload causes failed electrical defibrillation and post-shock reinitiation of fibrillation. J Mol Cell Cardiol 1998; 30:2183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999; 79:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Epstein AE, Kay GN, Plumb VJ, et al. Gross and microscopic pathological changes associated with nonthoracotomy implantable defibrillator leads. Circulation 1998; 98:1517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hurst TM, Hinrichs M, Breidenbach C, et al. Detection of myocardial injury during transvenous implantation of automatic cardioverter-defibrillators. J Am Coll Cardiol 1999; 34:402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joglar JA, Kessler DJ, Welch PJ, et al. Effects of repeated electrical defibrillations on cardiac troponin I levels. Am J Cardiol 1999; 83:270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poelaert J, Jordaens L, Visser CA, et al. Transoesophageal echocardiographic evaluation of ventricular function during transvenous defibrillator implantation. Acta Anaesthesiol Scand 1996; 40:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Runsiö M, Bergfeldt L, Brodin LA, et al. Left ventricular function after repeated episodes of ventricular fibrillation and defibrillation assessed by transoesophageal echocardiography. Eur Heart J 1997; 18:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sears SE Jr, Conti JB. Understanding implantable cardioverter defibrillator shocks and storms: medical and psychosocial considerations for research and clinical care. Clin Cardiol 2003; 26:107.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1058 Version 50.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8616726" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : An overview of antiarrhythmic drug management of electrical storm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17970963" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Electrical storm in patients with an implanted defibrillator: a matter of definition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7586312" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2220581" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Long-term follow-up in patients with incessant ventricular tachycardia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29097296" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9857871" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Electrical storm in patients with transvenous implantable cardioverter-defibrillators: incidence, management and prognostic implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11319196" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Electrical storm presages nonsudden death: the antiarrhythmics versus implantable defibrillators (AVID) trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17954398" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Ventricular arrhythmia storms in postinfarction patients with implantable defibrillators for primary prevention indications: a MADIT-II substudy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26884622" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Management of a Patient With Electrical Storm: Role of Epicardial Catheter Ablation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15763536" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Electrical storm is an independent predictor of adverse long-term outcome in the era of implantable defibrillator therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10933373" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Clusters of ventricular tachycardias signify impaired survival in patients with idiopathic dilated cardiomyopathy and implantable cardioverter defibrillators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16008807" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Characteristics and relevance of clustering ventricular arrhythmias in defibrillator recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17050586" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Electrical storm in patients with an implantable defibrillator: incidence, features, and preventive therapy: insights from a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16442402" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Prevalence and predictors of electrical storm in patients with implantable cardioverter-defibrillator.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15574176" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Prevalence, predictors, and mortality significance of the causative arrhythmia in patients with electrical storm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16421175" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Clinical predictors and prognostic significance of electrical storm in patients with implantable cardioverter defibrillators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21156679" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Predictors of electrical storm recurrences in patients with implantable cardioverter-defibrillators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28314850" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Temporal Trends and Temperature-Related Incidence of Electrical Storm: The TEMPEST Study (Temperature-Related Incidence of Electrical Storm).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11227599" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Is electrical storm in ICD patients the sign of a dying heart? Outcome of patients with clusters of ventricular tachyarrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9183044" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Incidence and clinical significance of short-term recurrent ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillator.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20956224" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25172845" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10486418" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7586313" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8522712" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. Intravenous Amiodarone Multicenter Trial Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21494516" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The evaluation and management of electrical storm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36017572" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29699616" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Propranolol Versus Metoprolol for Treatment of Electrical Storm in Patients With Implantable Cardioverter-Defibrillator.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10942741" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Treating electrical storm : sympathetic blockade versus advanced cardiac life support-guided therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17692746" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Bradycardia pacing-induced short-long-short sequences at the onset of ventricular tachyarrhythmias: a possible mechanism of proarrhythmia?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25173339" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30165437" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : 2018 ESC/EACTS Guidelines on myocardial revascularization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18172038" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Catheter ablation for the treatment of electrical storm in patients with implantable cardioverter-defibrillators: short- and long-term outcomes in a prospective single-center study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21529742" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Catheter ablation of electrical storm in a collaborative hospital network.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22431442" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Catheter ablation of ventricular fibrillation triggers and electrical storm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23264584" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Venturing into ventricular arrhythmia storm: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28843418" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Successful ventricular tachycardia ablation in patients with electrical storm reduces recurrences and improves survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32281407" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Catheter Ablation in Patients With Cardiogenic Shock and Refractory Ventricular Tachycardia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22696517" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Ablation or conservative management of electrical storm due to monomorphic ventricular tachycardia: differences in outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15051644" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20479150" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Neuraxial modulation for refractory ventricular arrhythmias: value of thoracic epidural anesthesia and surgical left cardiac sympathetic denervation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22192676" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Bilateral cardiac sympathetic denervation for the management of electrical storm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12419728" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Propofol for electrical storm; a case report of cardioversion and suppression of ventricular tachycardia by propofol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24291775" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Cardiac sympathetic denervation in patients with refractory ventricular arrhythmias or electrical storm: intermediate and long-term follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29270467" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Efficacy of Stellate Ganglion Blockade in Managing Electrical Storm: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28471068" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Stellate ganglion blockade and bilateral cardiac sympathetic denervation in patients with life-threatening ventricular arrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28833780" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Stellate ganglion blockade for the treatment of refractory ventricular arrhythmias: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33358672" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Stellate Ganglion Blockade With Continuous Infusion Versus Single Injection for Treatment of Ventricular Arrhythmia Storm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34312821" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Stellate ganglion blockade for treating refractory electrical storm: a historical cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36725213" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Stellate ganglion block catheters for refractory electrical storm: a retrospective cohort and care pathway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31514529" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Effective Use of Percutaneous Stellate Ganglion Blockade in Patients With Electrical Storm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32372071" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Case Series of Transcutaneous Magnetic Stimulation for Ventricular Tachycardia Storm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28641796" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Cardiac Sympathetic Denervation for Refractory Ventricular Arrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33812839" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Long-Term Outcomes of Bilateral Cardiac Sympathetic Denervation for Refractory Ventricular Tachycardia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33888265" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Outcome of a Modified Sympathicotomy for Cardiac Neuromodulation of Untreatable Ventricular Tachycardia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24389229" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Safety and efficacy of renal denervation as a novel treatment of ventricular tachycardia storm in patients with cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33786832" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Renal sympathetic denervation for the treatment of recurrent ventricular arrhythmias-ELECTRAM investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29236642" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Noninvasive Cardiac Radiation for Ablation of Ventricular Tachycardia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31121018" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Stereotactic radiosurgery for ablation of ventricular tachycardia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9925356" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Ventricular fibrillation-induced intracellular Ca2+ overload causes failed electrical defibrillation and post-shock reinitiation of fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9922372" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Molecular mechanisms of myocardial remodeling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9769305" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Gross and microscopic pathological changes associated with nonthoracotomy implantable defibrillator leads.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10440152" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Detection of myocardial injury during transvenous implantation of automatic cardioverter-defibrillators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10073835" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Effects of repeated electrical defibrillations on cardiac troponin I levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8908228" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Transoesophageal echocardiographic evaluation of ventricular function during transvenous defibrillator implantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9049524" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Left ventricular function after repeated episodes of ventricular fibrillation and defibrillation assessed by transoesophageal echocardiography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12685615" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Understanding implantable cardioverter defibrillator shocks and storms: medical and psychosocial considerations for research and clinical care.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
